ネフローゼ症候群におけるDipyridamole (Persantin®)の臨床効果

DOI Web Site PubMed

書誌事項

タイトル別名
  • Clinical Effects of Dipyridamole (Persantin®) on Nephrotic Syndrome
  • ネフローゼ ショウコウグン ニ オケル Dipyridamole Persan
  • Multiclinic Double Blind Test
  • ―多施設二重盲検試験―

この論文をさがす

説明

Dipyridamole (Persantin) 300 mg/day, or its placebo were administered for 4 weeks to the nephrotic syndrome who had been treated by corticosteroids and their effects were compared by double blind method. 1) General improvement rate of Persantin (88.2%) was significantly (p<0.05) higher than that of placebo (46.7%) in steroid unresponsive nephrotic syndrome group. 2) As to urinary protein decreasing effect indicated by average decreasing rates of urinary protein in a week, the effect was better in Persantin group than in placebo group in the 1st and 2nd week. The same results were confirmed more evidently in the steroid unresponsive nephrotic syndrome group and also in those patient except minimal changes in histological classification. 3) As to the endogenous creatinine clearance, Persantin group showed a significantly large increase, compared with placebo group. 4) As to serum cholesterol level and triglycerid level, Persantin group showed a bigger tende-ncy to decrease, compared with placebo group. 5) As for side effects, headache, palpitation, nausea, retching, and others were observed in Persantin group. However, these were not serious and disappeared after discontinuation of administra-tion of the drug.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ